FindTrial
Sign In

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06441630
Enrollment
251
Registered
2024-06-04
Start date
2024-07-31
Completion date
2025-09-30
Last updated
2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Brief summary

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Detailed description

Essential Hypertension

Interventions

DRUGAD-227A

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGAD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGAD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGPlacebo of AD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGPlacebo of AD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Patients with Essential Hypertension * Other inclusions applied

Exclusion criteria

* Patient with Secondary Hypertension * Other exclusions applied

Design outcomes

Primary

MeasureTime frameDescription
Change in MSSBPBaseline to Week8Change from Baseline in Mean Sitting Systolic Blood Pressure

Countries

South Korea

Contacts

Primary ContactJeongEun Park
parkje@addpharma.co.kr+82-31-891-6989

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026